Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

from Decera Clinical Education Oncology Podcast · host Jacqueline S Garcia MD

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:Navitoclax (BCL-XL/BCL-2 inhibitor)Pelabresib (BET inhibitor)Imetelstat (telomerase inhibitor)Luspatercept (erythroid maturation agent)Additional strategiesPresenter: Jacqueline S. Garcia, MDAssistant Professor of MedicineHarvard Medical SchoolDana-Farber Cancer InstituteBoston, MassachusettsLink to the full program here. https://bit.ly/47z8WCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Nov 30, 2023

Embed this episode

Attribution link and audio player

What this episode covers

Listen to expert commentary on emerging strategies in clinical trial development for treating patients with myelofibrosis, with a focus on alternatives to JAK inhibitors.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

0:00 19:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Decera Clinical Education Oncology Podcast?

This episode is 19 minutes long.

When was this Decera Clinical Education Oncology Podcast episode published?

This episode was published on November 30, 2023.

Can I download this Decera Clinical Education Oncology Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!